ID

14000

Descrizione

Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT02511184

collegamento

https://clinicaltrials.gov/show/NCT02511184

Keywords

  1. 21/03/16 21/03/16 -
Caricato su

21 marzo 2016

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility ALK-positive Advanced NSCLC NCT02511184

Eligibility ALK-positive Advanced NSCLC NCT02511184

Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically or cytologically proved diagnosis of locally advanced recurrent or metastatic non-squamous nsclc that is not suitable for local curative treatment.
Descrizione

Non-Small Cell Lung Carcinoma

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0007131
alk-positive nsclc as determined by a test that is approved or validated for use as a companion diagnostic test.
Descrizione

Alk-positive nsclc

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C3888914
UMLS CUI [1,2]
C0007131
no prior systemic therapy for metastatic disease.
Descrizione

Neoplasm Metastasis

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0027627
adjuvant chemotherapy more than 12 months prior to study enrollment.
Descrizione

Adjuvant chemotherapy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0085533
Measurable disease as per recist 1.1
Descrizione

Measurable Disease

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1513041
Ecog ps 0 or 1.
Descrizione

ECOG

Tipo di dati

text

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior exposure to alk receptor tyrosine kinase inhibitor, anti-pd1, anti-pdl1 or any drug targeting t-cell checkpoint pathways.
Descrizione

ALK receptor tyrosine kinase assay

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3203742
Known diagnosis of immunodeficiency or is receiving systemic steroid therapy or other form of immunosuppressive therapy within 7 days of clinical trial treatment.
Descrizione

Immunologic Deficiency Syndromes

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021051
UMLS CUI [2]
C4039704
Active autoimmune disease that has required systemic treatment in the past 3 months.
Descrizione

Autoimmune Diseases

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0004364
history of extensive disseminated interstitial fibrosis or any grade of interstitial lung disease.
Descrizione

Lung Diseases

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0206062

Similar models

Eligibility ALK-positive Advanced NSCLC NCT02511184

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Non-Small Cell Lung Carcinoma
Item
histologically or cytologically proved diagnosis of locally advanced recurrent or metastatic non-squamous nsclc that is not suitable for local curative treatment.
boolean
C0007131 (UMLS CUI [1])
Alk-positive nsclc
Item
alk-positive nsclc as determined by a test that is approved or validated for use as a companion diagnostic test.
boolean
C3888914 (UMLS CUI [1,1])
C0007131 (UMLS CUI [1,2])
Neoplasm Metastasis
Item
no prior systemic therapy for metastatic disease.
boolean
C0027627 (UMLS CUI [1])
Adjuvant chemotherapy
Item
adjuvant chemotherapy more than 12 months prior to study enrollment.
boolean
C0085533 (UMLS CUI [1])
Measurable Disease
Item
Measurable disease as per recist 1.1
boolean
C1513041 (UMLS CUI [1])
ECOG
Item
Ecog ps 0 or 1.
text
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
ALK receptor tyrosine kinase assay
Item
prior exposure to alk receptor tyrosine kinase inhibitor, anti-pd1, anti-pdl1 or any drug targeting t-cell checkpoint pathways.
boolean
C3203742 (UMLS CUI [1])
Immunologic Deficiency Syndromes
Item
Known diagnosis of immunodeficiency or is receiving systemic steroid therapy or other form of immunosuppressive therapy within 7 days of clinical trial treatment.
boolean
C0021051 (UMLS CUI [1])
C4039704 (UMLS CUI [2])
Autoimmune Diseases
Item
Active autoimmune disease that has required systemic treatment in the past 3 months.
boolean
C0004364 (UMLS CUI [1])
Lung Diseases
Item
history of extensive disseminated interstitial fibrosis or any grade of interstitial lung disease.
boolean
C0206062 (UMLS CUI [1])

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial